ERBB2 and non-small cell lung carcinoma: In the latter, a total of 80 patients with HER2-mutant NSCLC who had received at least one prior line of treatment, mostly platinum-based chemotherapy, were randomized in a 2:1 ratio to receive T-DXd at a dose of 5.4 mg/kg or 6.4 mg/kg, respectively.